The global bioprocess analyzers market was valued at US$ 250 Mn in 2018 and is projected to expand at a CAGR of 10% from 2019 to 2027.
The global bioprocess analyzers market was valued at US$ 250 Mn in 2018 and is projected to expand at a CAGR of 10% from 2019 to 2027. Growth of the biopharmaceutical industry, flexibility in terms of customization, technological advancements, and increase in demand for vaccines are anticipated to boost the growth of the global bioprocess analyzers market from 2019 to 2027.
North America is expected to dominate the global bioprocess analyzers market in the next few years. Single use technologies have expanded at a higher rate, as an alternative to permanent reusable stainless steel fermenters.
Asia Pacific bioprocess analyzers market is estimated to propel by the maximum growth rate during the forecast period, owing to the developing biotechnology industry and technological advancement.
What are the Key Market Dynamics in the Global Bioprocess Analyzers Market?
Single use technologies provide technological advancements and cost-effective technologies owing to increase in capacities and capabilities. Disposable systems are usually preferred in early stage development; however, stainless steel bioreactors are widely utilized for full-scale production in the global bioprocess analyzers market
Major companies enter into distribution agreements to expand their footprint across the world. Technological advancements and mergers & acquisitions are likely to propel the global bioprocess analyzers market during the forecast period.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=46311
Opportunities for manufacturers targeting large production volumes. A majority of stainless steel facilities are now being constructed in developing countries to cater to large volume demand in the global bioprocess analyzers market. Stainless steel facilities, although being phased out steadily due to surge in popularity of single-use technology, will remain an opportunity area for the global bioprocess analyzers market.
What are the Key Challenges Witnessed by the Global Bioprocess Analyzers Market?
Demand for personalized medicine, (stratified medicine), is increasing at a rapid pace- the trend toward stratified therapeutics will also call for changes in bioprocessing equipment design especially used in small scale production units. This might be a challenge for the global bioprocess analyzers market in the upcoming period.
Bioprocessing equipment developed for continuous biopharmaceutical manufacturing are relatively small-sized; however, integrating upstream and downstream bioprocessing can be a challenge for the global bioprocess analyzers market.
Request for Analysis of the COVID19 Impact on Bioprocess Analyzers Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=46311
Consumables and Accessories Segment to Capture Largest Share
New product development and increase in efficiency of different media used for cell culture production are anticipated to boost the consumables & accessories segment in the global bioprocess analyzers market next few years.
Recombinant Proteins Segment to Grow at Rapid Pace
- Increase in research studies to understand protein-protein interaction to perform several diagnostic tests such as ELISA and RIA is likely to augment the recombinant protein segment in the global bioprocess analyzers market during the forecast period.
- Increase in research activities by several research institutes and biotech companies for the pre-diagnosis of chronic diseases propels the same segment in the global bioprocess analyzers market during the forecast period.
- Demand for human and humanized monoclonal antibodies is increasing due to the rise in prevalence of several chronic diseases such as cancer and HIV- which might be a factor for the growth of the monoclonal antibodies segment in the global bioprocess analyzers market in the upcoming future.
Biopharmaceutical Companies Segment to Account for Largest Share
Increase in demand for therapeutic proteins produced through mammalian expression systems is likely to drive the biopharmaceutical companies segment in the global bioprocess analyzers market during the forecast period owing to rise in usage of bioprocess instruments by biotechnology and pharmaceutical companies to manufacture biopharmaceutical products such as biologics, drugs, and regenerative medicines.
A contract manufacturing organization offers important cost benefits over an organization’s internal production facilities- which might be the factor for the growth of the contract research organizations segment in the global bioprocess analyzers market during the forecast period.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=46311
North America to Account for Largest Market Share
- High competition, increase in R&D expenditure of pharmaceutical and biotechnology companies, and shift of contract research organizations toward Asia Pacific fuel the growth of the bioprocess analyzers market in Asia Pacific
- In terms of revenue, North America dominated the global bioprocess analyzers market in 2018. Higher adoption of advanced bioprocess products in R&D in the life sciences industry propels the bioprocess analyzers market in North America.
Hoffmann-La Roche Ltd., Nova Biomedical, and Randox Laboratories Ltd. to Lead Market
- Hoffmann-La Roche Ltd., Nova Biomedical, and Randox Laboratories Ltd. are the major players in the global bioprocess analyzers market, offering products with proprietary technologies.
- Other players in the global bioprocess analyzers market include Sartorius Group, YSI, Inc. (Xylem, Inc.), Optocell GmbH & Co. KG, Kaiser Optical Systems, Inc., and SYSBIOTECH GmbH.
- Key mergers and acquisitions, technological advancements, and product promotion are the various competitive strategies adopted by the major companies in order to sustain the global bioprocess analyzers market.
- In December 2018, Randox Laboratories won the Industrial Strategy Challenge Fund (ISCF) award from the U.K. Research and Innovation. The award was worth US$ 888,318 which was invested in research and development.
- For example, in June 2018, Bio-Techne Corporation, a leading developer and manufacturer of growth factors, antibodies, and immunoassays announced plans to acquire Quad Technologies.
- Spectrum, Inc., a privately held bioprocess filtration specialist, merged with life sciences company Repligen Corp in July 2017.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700
Albany NY - 12207United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com